- Home
- AGIO vs TFIN Comparison
AGIO vs TFIN Comparison
Compare AGIO & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- TFIN
- Stock Information
- Founded
- AGIO 2007
- TFIN 1981
- Country
- AGIO United States
- TFIN United States
- Employees
- AGIO N/A
- TFIN N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- TFIN Major Banks
- Sector
- AGIO Health Care
- TFIN Finance
- Exchange
- AGIO Nasdaq
- TFIN Nasdaq
- Market Cap
- AGIO 1.4B
- TFIN 1.3B
- IPO Year
- AGIO 2013
- TFIN N/A
- Fundamental
- Price
- AGIO $32.09
- TFIN $57.77
- Analyst Decision
- AGIO Buy
- TFIN Hold
- Analyst Count
- AGIO 8
- TFIN 6
- Target Price
- AGIO $56.00
- TFIN $68.50
- AVG Volume (30 Days)
- AGIO 550.4K
- TFIN 220.0K
- Earning Date
- AGIO 05-01-2025
- TFIN 07-16-2025
- Dividend Yield
- AGIO N/A
- TFIN N/A
- EPS Growth
- AGIO N/A
- TFIN N/A
- EPS
- AGIO 11.45
- TFIN 0.37
- Revenue
- AGIO $37,035,000.00
- TFIN $401,390,000.00
- Revenue This Year
- AGIO $27.43
- TFIN $12.09
- Revenue Next Year
- AGIO $189.81
- TFIN $14.37
- P/E Ratio
- AGIO $2.80
- TFIN $155.12
- Revenue Growth
- AGIO 25.96
- TFIN 0.68
- 52 Week Low
- AGIO $23.42
- TFIN $42.90
- 52 Week High
- AGIO $62.58
- TFIN $110.58
- Technical
- Relative Strength Index (RSI)
- AGIO 65.51
- TFIN 50.31
- Support Level
- AGIO $29.05
- TFIN $52.77
- Resistance Level
- AGIO $30.45
- TFIN $61.11
- Average True Range (ATR)
- AGIO 1.13
- TFIN 2.57
- MACD
- AGIO 0.33
- TFIN -0.26
- Stochastic Oscillator
- AGIO 91.98
- TFIN 47.44
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.